Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
暂无分享,去创建一个
J. Schellens | L. Siu | A. Hansen | M. Demario | A. Huitema | M. Simcox | D. Jonker | D. Geho | G. Goss | D. Meulendijks | V. Karanikas | U. Lassen | D. Bottino | M. Mau-Sørensen | K. Schostack | Hua Zhong | Suzana M Vega-Harring | Tiantom Jarutat | Markus Roessler | Karen Wang | M. DeMario